CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP) reported second quarter 2026 results and progress on its strategic transformation toward a diversified, high-value pipeline. Cash and cash equivalents were approximately $20.0 million at June 30, 2026, up from $7.2 million at year-end 2025, largely driven by an oversubscribed private placement that generated $22.5 million in gross proceeds ($20.7 million net).

The company believes this cash will fund planned operations beyond the next twelve months as it pursues in-licensing or acquisition of one or more assets by year-end 2026. CNS completed its global Berubicin glioblastoma trial and is closing out the study while engaging in out-licensing discussions for Berubicin and TPI 287. Second-quarter 2026 R&D expenses were $1.2 million, G&A expenses were $1.5 million, and net loss was $2.6 million, or $0.37 per share. A May 2026 financing expanded the shareholder base with biotech-focused institutional investors and the board was strengthened with the appointment of life sciences executive Michal Fisher.

Positive

• Cash balance $20.0 million at June 30, 2026
• Financing $22.5 million gross ($20.7 million net) closed May 2026
• Runway cash expected to fund operations beyond next twelve months
• Berubicin trial global glioblastoma study enrollment and treatment completed
• Shareholder base broadened with biotech-focused institutional investors
• Board strengthened by adding dealmaking-experienced director Michal Fisher

Negative

• Net loss approximately $2.6 million in Q2 2026
• G&A expenses increased to $1.5 million from $1.2 million
• Share count 10,604,928 fully diluted versus 1,461,449 common shares outstanding

News Explained

The closed May financing included 650,000 issued shares and pre-funded warrants for 9,143,479 additional shares at a $0.001 exercise price; those warrants can increase the share count, while resale registration does not give CNS further proceeds.

Market Context

A director's Form 4 reported Net Buying through a 7,100-share purchase, adding insider context to th...

Analysis

A director's Form 4 reported Net Buying through a 7,100-share purchase, adding insider context to the earnings report. The active resale registration and the company's continuing net loss remain material risks to monitor.

Key Figures

Cash and equivalents: $20.0M vs. $7.2M Gross financing proceeds: $22.5M Net financing proceeds: $20.7M +5 more

8 metrics

Cash and equivalents $20.0M vs. $7.2M June 30, 2026 vs. December 31, 2025

Gross financing proceeds $22.5M May 2026 private placement

Net financing proceeds $20.7M May 2026 private placement

Operating runway Beyond 12 months Existing cash resources and planned operations

R&D expenses $1.2M vs. $1.2M Q2 2026 vs. Q2 2025

G&A expenses $1.5M vs. $1.2M Q2 2026 vs. Q2 2025

Net loss $2.6M vs. $2.4M Q2 2026 vs. Q2 2025

Net loss per share $0.37 vs. $6.42 Q2 2026 vs. Q2 2025, basic and diluted

Previous Earnings Reports

5 past events · Latest: May 14 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 14	Q1 earnings report	Negative	-9.2%	Higher expenses and wider loss accompanied strategic transformation and post-quarter financing.
Nov 17	Q3 earnings report	Positive	-2.9%	Lower loss and expenses, plus TPI 287 activity, preceded a negative reaction.
Aug 15	Q2 earnings report	Positive	-15.6%	Promising TPI 287 results and improved loss preceded a negative reaction.
May 16	Q1 earnings report	Negative	+1.6%	Higher loss and R&D costs contrasted with reported Phase 1 activity.
Apr 01	FY 2024 earnings report	Negative	-5.2%	Berubicin missed its primary endpoint alongside reduced loss and financing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings events averaged a -6.26% 24-hour reaction, with negative reactions in three of five events.

Key Terms

private placement, pre-funded warrants, out-licensing, glioblastoma multiforme

4 terms

private placement financial

"closed a private placement with institutional investors"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"10,604,928 shares fully diluted including pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

out-licensing financial

"pursuing out-licensing discussions for both Berubicin and TPI 287"

Out-licensing is when a company grants another firm the right to develop, manufacture or sell a product or technology in exchange for upfront payments, milestone fees and ongoing royalties. Think of it like leasing a recipe to a larger kitchen so they handle production and sales while the original owner collects steady income and reduces costs and risk. For investors, out-licensing can speed commercialization, create near-term revenue, lower development expenses, and shift where future profits and growth will come from.

glioblastoma multiforme medical

"global clinical trial of Berubicin for glioblastoma multiforme"

An aggressive form of brain cancer that grows quickly and spreads into nearby brain tissue, often causing severe symptoms and limited treatment options. For investors, glioblastoma matters because it defines a high unmet medical need and a potentially large market for new drugs, devices, or diagnostics; success or failure in clinical trials and regulatory reviews for glioblastoma treatments can dramatically affect the valuation and risk profile of healthcare companies, like a make-or-break product for a small biotech.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline

HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026.

"We are moving with speed and discipline to transform this company," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "In the second quarter, we significantly strengthened our balance sheet and added new expertise to our Board to enable us to build a differentiated, high-value pipeline of innovative therapies. We are executing with urgency and are confident that the actions we've taken this year strengthen CNS Pharmaceuticals ability to create meaningful value going forward."

Strategic and Corporate Highlights

• New corporate strategy in motion. Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team's multi-functional experience across high-value therapeutic areas. As previously stated, the Company expects to in-license or acquire one or more assets by year end 2026.

• Oversubscribed $22.5 million financing closed. On May 5, 2026, the Company closed a private placement with institutional investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners, generating approximately $22.5 million in gross proceeds ($20.7 million net), significantly reinforcing the Company's capital and shareholder base in support of its new strategy.

• Board strengthened with dealmaking depth. The Company appointed Michal Fisher, a life sciences executive with a track record in business development, licensing and capital formation, including prior leadership roles in strategic alliances and corporate development to its Board of Directors in May 2026.

• Legacy programs advancing toward closure. The Company's global clinical trial of Berubicin for glioblastoma is complete. The Company is now focused on closing out the study while pursuing out-licensing discussions for both Berubicin and TPI 287.

Since announcing its new corporate strategy in March 2026, the Company has focused on leveraging the experience of its leadership team to identify promising development-stage therapeutic assets that align with its strategy of building a diversified pipeline targeting serious diseases. Management is actively evaluating business development opportunities while maintaining financial discipline and preserving capital for future growth initiatives.

"This quarter reflects the deliberate work of resetting CNS Pharmaceuticals for its next chapter," said Steve O'Loughlin, Chief Financial Officer. "With a fortified balance sheet, extended capital runway, and new shareholder base comprised of biotech focused institutional investors, we are well positioned to execute our strategy with an enhanced ability to transact."

Second Quarter 2026 Financial Results

Cash and cash equivalents were approximately $20.0 million as of June 30, 2026, compared to $7.2 million as of December 31, 2025. The increase primarily reflects the Company's previously announced private placement financing completed in May 2026. The Company believes its existing cash resources are sufficient to fund planned operations beyond the next twelve months as it continues executing its strategic business development initiatives.

Research and development expenses were approximately $1.2 million for the second quarter of 2026, compared to $1.2 million for the same period in 2025. Research and development expenses included activities related to completing and closing out the Berubicin clinical trial, as enrollment and patient treatment have been completed. Future research and development expenses will depend on the timing and nature of any assets the Company acquires or licenses and the associated development activities.

General and administrative expenses were approximately $1.5 million for the second quarter of 2026, compared to $1.2 million for the same period in 2025. The increase was primarily attributable to higher headcount-related expenses, partially offset by lower professional services costs.

Net loss for the second quarter of 2026 was approximately $2.6 million, or $0.37 per basic and diluted share, compared to a net loss of approximately $2.4 million, or $6.42 per basic and diluted share, for the second quarter of 2025.

As of August 14, 2025, the Company had 1,461,449 common shares of stock outstanding and 10,604,928 shares fully diluted including pre-funded warrants that were issued in its May 2026 financing.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

Business Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

What were CNS Pharmaceuticals (NASDAQ:CNSP) cash and runway as of Q2 2026?

CNS Pharmaceuticals reported approximately $20.0 million in cash as of June 30, 2026. According to CNS Pharmaceuticals, this balance is believed to be sufficient to fund planned operations beyond the next twelve months while it executes its business development strategy.

What financing did CNSP complete in May 2026 and how much was raised?

CNS Pharmaceuticals closed an oversubscribed private placement on May 5, 2026, raising $22.5 million in gross proceeds. According to CNS Pharmaceuticals, the financing generated about $20.7 million in net proceeds and significantly reinforced its capital position and biotech-focused institutional shareholder base.

How is CNS Pharmaceuticals changing its corporate strategy in 2026?

CNS Pharmaceuticals is pivoting from a singular focus on glioblastoma to a diversified, high-value pipeline. According to CNS Pharmaceuticals, management aims to in-license or acquire one or more development-stage therapeutic assets by year-end 2026 while maintaining financial discipline.

What is the status of CNSP’s Berubicin glioblastoma program in 2026?

CNS Pharmaceuticals has completed its global clinical trial of Berubicin for glioblastoma, with enrollment and patient treatment finished. According to CNS Pharmaceuticals, the company is closing out the study and pursuing out-licensing discussions for both Berubicin and TPI 287.

What were CNS Pharmaceuticals’ key expenses and net loss in Q2 2026?

For the second quarter of 2026, CNS Pharmaceuticals reported R&D expenses of about $1.2 million and G&A expenses of about $1.5 million. According to CNS Pharmaceuticals, net loss was approximately $2.6 million, or $0.37 per basic and diluted share.

How many CNSP shares were outstanding and fully diluted after the May 2026 financing?

As of August 14, 2025, CNS Pharmaceuticals reported 1,461,449 common shares outstanding and 10,604,928 shares on a fully diluted basis. According to CNS Pharmaceuticals, the fully diluted figure includes pre-funded warrants issued in its May 2026 private placement financing.